Browsing by Author "Uribe Uribe, Diego Fernando"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Item Nanopartículas como vehículos de agentes con actividad anticancerígena: Revisión sistemática(Universidad Santiago de Cali, 2025-12-10) Uribe Uribe, Diego Fernando; Ciro Monsalve, Yhors Alexander (Director)Nanoparticles as carriers of agents with anticancer activity enhance the pharmacological action of drugs, extend their lifespan, and reduce treatment-related toxicity. Formulations based on biodegradable polymers such as chitosan, hyaluronic acid, or poly(lactic-co-glycolic acid) (PLGA) improve stability, biocompatibility, and active targeting toward specific receptors, thereby increasing pharmacotherapeutic efficacy. However, significant limitations persist in clinical validation, primarily due to the lack of pharmacokinetic, biodistribution, and long-term toxicity data in therapeutic applications. The development of nanoparticles responsive to multiple stimuli—such as pH, light, temperature, and redox potential—enables the integration of combined therapies that reduce cytotoxicity and allow for more precise and controllable treatments, improving efficiency and decreasing cellular resistance. Controlled delivery systems ensure greater safety and a reduction in carcinogenic activity.Studies investigating nanoparticles as carriers of anticancer agents, mechanisms of action, nanosystem characterization, and therapeutic performance were reviewed. A total of 79 articles published between 2020 and 2025 were analyzed from Nature, Oxford Journals, PubMed, Scopus, ScienceDirect, SpringerLink, and Taylor & Francis, all of which evaluated the antitumor activity of these compounds. Nanoencapsulation systems, controlled release mechanisms, active targeting strategies, stimuli-responsive release, and targeted therapies involving hybrid, inorganic, lipidic, polymeric, and protein nanoparticles were identified. The encapsulated substances included curcumin, diosgenin, doxorubicin, plant-derived compounds, and evodiamine, highlighting their pharmacological activity in inhibiting cancer cell proliferation.The reported advances demonstrated significant progress in optimizing the use of nanoparticles as drug delivery vehicles, offering improved therapeutic efficacy and treatment adherence in clinical practice.